Alethia Biotherapeutics

Insight from Yves Cornellier, President and CEO Alethia Biotherapeutics

“Nearly half of all Canadian biopharmaceutical activity is concentrated in Québec, particularly in the Montréal area. Over the years, we have benefited from collaborations with universities and the Biotechnology Research Institute (NRC-BRI). The Greater Montréal cluster has everything you need for the development of drugs, from basic research through to commercialization—an extraordinary asset.”

Yves Cornellier, President and CEO Alethia Biotherapeutics